FDA OK's Gilead's 'TAF' Combo HIV Drug Odefsey
This article was originally published in Scrip
Executive Summary
Gilead Sciences Inc. on March 1 gained the FDA's approval to market Odefsey as a treatment for HIV-1 infection – the second so-called TAF-based regimen to win the agency's OK.
You may also be interested in...
Gilead, With Two PRVs In Hand, Holds Options For Accelerating Late-Stage Pipeline
Likely candidates for use of Gilead's priority review vouchers include GS-4997, a Phase III candidate for NASH, and bictegravir, its second-generation integrase inhibitor for HIV. The virology specialist previously used a PRV successfully to accelerate approval of Odefsey.
3Q Pharma Results Preview: Pfizer, Gilead, Allergan, Valeant, AstraZeneca
Pfizer, Gilead, Allergan, Valeant and AstraZeneca are among the pharma and biotech companies still to report their third-quarter results. After Merck, Bristol-Myers, Lilly, Amgen, Novartis, Sanofi and others revealed their July-to-September performance, Scrip takes a look at what to expect in the weeks ahead.
2Q Pharma Results Preview: What Lies Ahead
The big pharma financial reporting season gets underway on July 19 with Novartis and Johnson & Johnson in the vanguard. Biosimilar threats to immunology and cancer drugs and new product ramp-ups are among the key things to watch for as results are announced.